debrisoquin has been researched along with 2-hydroxyimipramine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brøsen, K; Meyer, UA; Zeugin, T | 1 |
| Bech, P; Bertilsson, L; Brøsen, K; Gram, LF; Klysner, R; Otton, SV | 1 |
1 trial(s) available for debrisoquin and 2-hydroxyimipramine
| Article | Year |
|---|---|
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Debrisoquin; Depression; Desipramine; Female; Humans; Hydroxylation; Imipramine; Isoquinolines; Kinetics; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Sparteine | 1986 |
1 other study(ies) available for debrisoquin and 2-hydroxyimipramine
| Article | Year |
|---|---|
Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Topics: Antibodies; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; DNA; Humans; Imipramine; Isoenzymes; Kidney; Kinetics; Methotrimeprazine; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Polymorphism, Genetic; Quinidine; Sparteine; Transfection | 1991 |